Ionis Pharmaceuticals shares rise 4.94% intraday after reporting strong Q2 earnings and revenue growth.

Ionis Pharmaceuticals, Inc. rose 4.94% intraday, with the company reporting strong second-quarter earnings results. Revenue increased to USD 452 million from USD 225 million a year ago, and net income turned to a profit of USD 124 million from a net loss of USD 66 million. The company also expects additional advancements in the second half of the year, including the launch of donidalorsen for hereditary angioedema and important Phase 3 results for olezarsen in severe hypertriglyceridemia and zilganersen.